Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, and State of the Finances
CY Ha, A Kornbluth - Treatment of Inflammatory Bowel Disease with …, 2018 - Springer
Biosimilars are defined as highly similar but not chemically identical to the original (also
known as the reference) biologic drug. In order to obtain regulatory approval, an anti-TNF …
known as the reference) biologic drug. In order to obtain regulatory approval, an anti-TNF …
[PDF][PDF] Improving the clinical pathway for Crohn's perianal fistulas: novel approaches to aetiopathogenesis, treatment and outcome measurement
S Adegbola - 2021 - core.ac.uk
Crohn's perianal fistulas are often complex and represent a challenging and disabling
disease phenotype with unknown optimal treatment strategy. There are paucities in …
disease phenotype with unknown optimal treatment strategy. There are paucities in …
[PDF][PDF] COVİD-19 da Sitokinler ve COVİD-19 Tedavisinde Kullanılan İlaçlar Arasında Potansiyel İlaç Etkileşimleri Potential Interactions between Increased Cytokines in …
Öz COVID-19 enfeksiyonu sırasında virus ve konakçı hücre etkileşimleri çok güçlü immun
mediyatörlerin akut üretimine yol açmaktadır. Ağır klinik durum çoğunlukla virüsün …
mediyatörlerin akut üretimine yol açmaktadır. Ağır klinik durum çoğunlukla virüsün …
Retrospektive Analyse zum Vergleich des Einflusses einer frühen oder späten Intervention mit Tumornekrosefaktor-alpha-Antikörper-Therapie auf den …
T Seitz - 2020 - edoc.ub.uni-muenchen.de
Abstract Einleitung: TNFalpha-AK (TNF-AK) werden bei Morbus Crohn (MC) zunehmend
früher im Lauf der Erkrankung eingesetzt, da sie möglicherweise durch Verhinderung …
früher im Lauf der Erkrankung eingesetzt, da sie möglicherweise durch Verhinderung …
[PDF][PDF] Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn's Disease
HITKM Nagasakac, S Shinzakia, KKYSM Watanabef - 2020 - e-helvetica.nb.admin.ch
Induction therapy with tumor necrosis factor-α (TNF-α) inhibitors is highly effective for the
treatment of Crohn's disease. However, there are primary nonresponders (PNR) of TNF-α …
treatment of Crohn's disease. However, there are primary nonresponders (PNR) of TNF-α …
Prognosis of IBD in children and adolescents: Assessment of outcome, based on clinical, serological and microbial markers at diagnosis
C Olbjørn - 2019 - duo.uio.no
Pediatric inflammatory bowel disease (IBD) patients often present with an extensive disease
distribution and an aggressive disease course. The disease course is unpredictable. We …
distribution and an aggressive disease course. The disease course is unpredictable. We …
[PDF][PDF] Úloha genetických faktorů v diagnostice a predikci nespecifických střevních zánětů
MUDT Kupka - theses.cz
Crohnova nemoc je multifaktoriální zánětlivé onemocnění postihující zejména
gastrointestinální trakt. Z genetických faktorů uplatňujících se při rozvoji onemocnění jsou …
gastrointestinální trakt. Z genetických faktorů uplatňujících se při rozvoji onemocnění jsou …
Investigating CD8+ T-cell gene expression signatures as disease prognostic biomarkers in paediatric inflammatory bowel disease.
M Gasparetto - 2019 - repository.cam.ac.uk
Background: Currently, it is not possible to predict disease behaviour for children with
inflammatory bowel disease (IBD), which is a major obstacle in an era where we strive to …
inflammatory bowel disease (IBD), which is a major obstacle in an era where we strive to …
Full interchangeability in regards to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease
KH Katsanos, K Papamichael… - Inflammatory Bowel …, 2018 - academic.oup.com
The introduction of biosimilars with similar efficacy and safety to the reference drug allows
for more cost-effective treatment options for patients with inflammatory bowel disease (IBD) …
for more cost-effective treatment options for patients with inflammatory bowel disease (IBD) …
Farmacovigilância dos Biossimilares em Portugal: o exemplo do Infliximab
SAG Barbosa - 2018 - repositorio.ul.pt
O biossimilar do Infliximab foi o primeiro da sua classe–anticorpos monoclonais–a surgir no
mercado, daí a sua importância para ajudar a compreender o comportamento deste tipo de …
mercado, daí a sua importância para ajudar a compreender o comportamento deste tipo de …